Assessment and Treatment of Mild Cognitive Impairment

Diagnostic Evaluation

The American Academy of Neurology recommends that when cognitive concerns are raised, immediately proceed with validated cognitive assessments, functional evaluation, and systematic exclusion of reversible causes 1, 2
The Alzheimer's Association 2025 guidelines provide a hierarchical framework for diagnosing Mild Cognitive Impairment (MCI), which includes confirming subjective cognitive concern, objective cognitive impairment, and preserved functional independence 3, 4
Validated cognitive assessment tools include memory testing, executive function, language, visuospatial skills, and attention, such as the Trail Making Test and Boston Naming Test 5
Neuropsychological evaluation is the gold standard for demonstrating cognitive deficits and improving diagnostic accuracy beyond brief cognitive screens 3, 4, 6

Determine the predominant cognitive domain affected, such as amnestic MCI, non-amnestic MCI, or single/multiple domain involvement 5, 6
Atypical presentations include visual variant (posterior cortical atrophy) or language variant (logopenic aphasia), both consistent with MCI due to Alzheimer's disease 5

Systematically exclude critical reversible causes, such as medications (anticholinergics, benzodiazepines, opioids), metabolic disorders (hypoglycemia, hyperglycemia, hyponatremia), infections (urinary tract infections, pneumonia), and cerebrovascular events (stroke, multiple lacunar infarcts) 7, 2, 8
Essential laboratory evaluation includes complete blood count, comprehensive metabolic panel, thyroid function tests, vitamin B12 level, and urinalysis 7
Neuroimaging (preferably MRI) is essential for detecting vascular changes, structural lesions, and patterns characteristic of neurodegenerative diseases 7

Aggressive treatment of vascular risk factors is strongly recommended, including hypertension management according to guidelines, stroke prevention, and diabetes management 2, 8, 9
Lifestyle modifications, such as cognitive stimulation and training, regular physical exercise, and dietary modifications (Mediterranean-style diet patterns), have the strongest evidence for potentially slowing progression 2, 8

Annual screening for cognitive impairment is indicated for adults ≥65 years to detect progression, with more frequent monitoring based on individual risk factors and rate of decline 9, 5
Avoid hypoglycemia in diabetic patients, as it increases risk of cognitive decline, and adjust glycemic targets based on cognitive status (A1C <8.0-8.5% for those with cognitive impairment) 9

A borderline MoCA score does not definitively indicate mild cognitive impairment (MCI) and requires comprehensive clinical evaluation including functional assessment, informant reports, and exclusion of reversible causes before making this diagnosis 10
The distinction between MCI and dementia must be made on the basis of clinical assessment of cognition AND function, not screening scores alone 10

Use validated functional assessment tools such as the Pfeffer Functional Activities Questionnaire (FAQ) or Disability Assessment for Dementia (DAD) to determine if the patient maintains independence in instrumental activities of daily living 10
Obtain collateral history using structured instruments like the Ascertain Dementia 8 (AD-8) questionnaire or Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) 10
Combining cognitive tests with functional screens and informant reports improves diagnostic accuracy 10

When encountering a borderline MoCA score (23-25/30), obtain detailed informant report using AD-8 or IQCODE 10
Assess functional independence using FAQ or DAD 10
Screen for depression using PHQ-9 10
If functional independence is preserved, reversible causes are excluded, and objective cognitive impairment is confirmed on comprehensive testing, then MCI diagnosis can be established, otherwise consider dementia rather than MCI 10